Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Phase 3 N=80 Bacterial Decolonization to Prevent Radiation Dermatitis
Radiation Dermatitis
Primary: Number of Participants With Incidence of High Grade Radiation Dermatitis — 0; 9 Participants — p=0.004
N/A N=20 Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
Postoperative Wound Infection Deep Incisional Surgical Site · Prosthesis and Implants · Surgical Site Infection
Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants
Phase 1 N=15 Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Atopic Dermatitis Eczema
Primary: Relative Abundance of Staphylococcus Aureus Compared to Baseline — 0.106; 12.9 Relative abundance of S. aureus
Phase 2 N=12 Topical Treatment and Prevalence of P. Acnes
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Phase 1 N=36 A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Changes in Local Skin Reactions — 19; 11; 2; 1 Participants
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
Phase 1 N=10 A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Successful Engraftment of Probiotic Following a Single Application. — 2; 1 Participants
Phase 2 N=330 Study of Debio 1450 for Bacterial Skin Infections
Bacterial Infections
Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…
Phase 2 N=15 Topical NanoDox® for Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
Phase 2 N=54 Targeted Microbiome Transplant in Atopic Dermatitis
Atopic Dermatitis (AD)
Primary: Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events (TEAEs) — 0.19; 0.34 events per-participant-day — p=0.075
Phase 4 N=31 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
Phase 2 N=65 Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Impetigo · Secondarily Infected Traumatic Lesions
Primary: Participants With Clinical Cure According to Investigator's Assessment — 167; 184; 174; 36 Participants
Phase 4 N=70 Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Atopic Dermatitis · Secondary Infection
Primary: Bacteriological Culture — 13; 3; 16; 5 participants
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 3 N=850 Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…
Phase 2 N=256 A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up — 57; 50; 53 Participants
N/A N=15 Hidradenitis Suppurativa (HS) Tunneling Wounds
Hidradenitis Suppurativa
Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)
Phase 4 N=38 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Impetigo · Folliculitis · Secondarily Infected Eczema
Primary: Number of Participants Whose Wound Cultures Were Positive for MRSA and Who Were Determined to be a Clinical Success at the Follow-up Visit — 5 participants
Phase 4 N=7 Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans
Human Microbiome
Primary: Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization — -4174 fg/uL
Phase 4 N=25 Profiling the Skin Microbiome in Response to Altreno in Acne Patients
Acne · Healthy
Primary: CLR-transformed Abundance of Any Significant Taxa — 3.29; -2.49; -1.59; -2.75 Relative Abundance
Phase 3 N=199 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Methicillin-Resistant Staphylococcus Aureus · Bacterial Infections · Staphylococcal Skin Infections
Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants
N/A N=35 Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds
Healthy Volunteers
Primary: Microbial Community Richness - Baseline (Day 0) — 56.5862069; 32.13043478; 43.72413793; 34.03703704 Number of bacterial taxa — p=0.071225
Phase 4 N=7 Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Psoriasis Vulgaris
Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale
N/A N=34 Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Acne
Primary: Level of IL-1β — 52.5; 361.2 pg/mg
Phase 3 N=739 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants
Phase 2 N=100 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03